Kura Oncology (KURA) Gross Margin (2025 - 2026)
Kura Oncology (KURA) reported Gross Margin of 98.57% for Q1 2026, down 143.0% year-over-year from 229.22% in Q1 2025, and down 1.43% on a QoQ basis from 100.0% in Q1 2025.
Kura Oncology (KURA) has 2 years of Gross Margin data on file, last reported at 98.57% in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 98.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.57% |
| Mar 31, 2025 | 100.00% |